Downstaging Techniques for Hepatocellular Carcinoma in Candidates Awaiting Liver Transplantation

Area of Science:

• Hepatobiliary Surgery
• Transplant Oncology
• Hepatocellular Carcinoma Research

Background:

• Hepatocellular carcinoma (HCC) management has evolved, with downstaging expanding liver transplant eligibility.
• Locoregional and systemic therapies for HCC are continuously advancing.
• Downstaging protocols demonstrate significant success in improving transplant candidacy.

Purpose of the Study:

• To review current downstaging techniques for hepatocellular carcinoma.
• To analyze the indications, complications, and efficacies of existing downstaging methods.
• To explore emerging therapies, including neoadjuvant immunotherapy, for HCC.

Main Methods:

• Literature review of downstaging techniques for HCC.
• Analysis of clinical trial data on downstaging success.
• Evaluation of novel locoregional and systemic therapies.
• Assessment of immunotherapy's potential in the neoadjuvant setting.

Main Results:

• Downstaging protocols have successfully expanded the pool of liver transplant candidates.
• Established downstaging techniques show equitable long-term survival and recurrence rates post-transplant.
• Emerging therapies, particularly immunotherapy, show promise but require further investigation.

Conclusions:

• Downstaging is a validated strategy for optimizing HCC patients for liver transplantation.
• Current techniques are effective, but ongoing research is crucial for refining treatment paradigms.
• Immunotherapy represents a promising frontier in neoadjuvant HCC treatment.